Literature DB >> 24345220

Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.

Akiyuki Uzawa1, Masahiro Mori, Mori Masahiro, Satoshi Kuwabara.   

Abstract

Neuromyelitis optica (NMO) is characterized by severe optic neuritis and longitudinally extensive transverse myelitis. The discovery of an NMO-specific autoantibody to the aquaporin-4 (AQP4) water channel has improved knowledge of NMO pathogenesis. Many studies have focused on inflammatory and pathological biomarkers of NMO, including cytokines and chemokines. Increased concentrations of T helper (Th)17- and Th2-related cytokines and chemokines may be essential factors for developing NMO inflammatory lesions. For example, interleukin-6 could play important roles in NMO pathogenesis, as it is involved in the survival of plasmablasts that produce anti-AQP4 antibody in peripheral circulation and in the enhancement of inflammation in the central nervous system. Therefore, assessment of these useful biomarkers may become a supportive criterion for diagnosing NMO. Significant advances in the understanding of NMO pathogenesis will lead to the development of novel treatment strategies. This review focuses on the current advances in NMO immunological research, particularly that of cytokines and chemokines.
© 2013 International Society of Neuropathology.

Entities:  

Keywords:  Th17; chemokine; cytokine; interleukin-17; interleukin-6; neuromyelitis optica

Mesh:

Substances:

Year:  2014        PMID: 24345220     DOI: 10.1111/bpa.12097

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  25 in total

Review 1.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

2.  Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder.

Authors:  A Uzawa; M Mori; H Masuda; R Ohtani; T Uchida; R Aoki; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2020-07-23       Impact factor: 4.330

Review 3.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

4.  Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders.

Authors:  Ying Zhang; Xiao-Ying Yao; Mei-Chun Gao; Jie Ding; Rong-Hua Hong; Hua Huang; Lei Zhuang; Yong-Gang Wang; Yong Hao; Yang-Tai Guan
Journal:  CNS Neurosci Ther       Date:  2017-11-06       Impact factor: 5.243

Review 5.  Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.

Authors:  Monika Bradl; Yoko Kanamori; Ichiro Nakashima; Tatsuro Misu; Kazuo Fujihara; Hans Lassmann; Jürgen Sandkühler
Journal:  Nat Rev Neurol       Date:  2014-07-29       Impact factor: 42.937

6.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

7.  NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG.

Authors:  Margaret E Walker-Caulfield; Yong Guo; Renee K Johnson; Christina B McCarthy; Patrick D Fitz-Gibbon; Claudia F Lucchinetti; Charles L Howe
Journal:  J Neuroinflammation       Date:  2015-09-30       Impact factor: 8.322

8.  Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica.

Authors:  Fumitaka Shimizu; Hideaki Nishihara; Yasuteru Sano; Yukio Takeshita; Shiori Takahashi; Toshihiko Maeda; Toshiyuki Takahashi; Masaaki Abe; Michiaki Koga; Takashi Kanda
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 9.  Hypersensitivity Responses in the Central Nervous System.

Authors:  Reza Khorooshi; Nasrin Asgari; Marlene Thorsen Mørch; Carsten Tue Berg; Trevor Owens
Journal:  Front Immunol       Date:  2015-10-07       Impact factor: 7.561

10.  Neutrophil-to-Lymphocyte Ratio on Admission is an Independent Risk Factor for the Severity of Neurological Impairment at Disease Onset in Patients with a First Episode of Neuromyelitis Optica Spectrum Disorder.

Authors:  Yongyan Zhou; Haojie Xie; Yi Zhao; Jinwei Zhang; Yanfei Li; Ranran Duan; Yaobing Yao; Yanjie Jia
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.